CIPLA - Swing Trade Analysis with AI Signals
← Back to ListKey Parameters
⭐ Swing Trade Rating: 4.2
Show all parameters (20 more)
🧾 Trade Setup
Entry Price: 1,371 ₹. Target Exit Level 1,520 ₹ – based on recent momentum and the industry PE multiple. Maintain a stop-loss order at 1,300 ₹ to manage risk given the significant profit variance last quarter. This represents a strong swing trading opportunity capitalizing on current revenue momentum within a reasonably valued sector.
✅ Positive
The stock is experiencing significant revenue growth, with FY26 reaching ₹28,000 crore – a substantial increase from the previous quarter’s PAT of ₹385 Cr. Furthermore, the recent USFDA nod for Ventolin has provided a positive catalyst, and DII holdings are increasing while FII holdings are decreasing.
⚠️ Limitation
[Corrected] Stock P/E (33.9) is actually LOWER than Industry PE (34.8), a discount to industry peers rather than a premium - treat the valuation framing below with that in mind. Despite strong revenue growth, the stock trades at a premium valuation (Stock P/E 33.9 vs Industry PE 34.8) and the PEG ratio of 3.24 indicates that earnings are growing faster than the market's expected growth rate. The substantial profit variance (-33.8%) between current and previous quarters warrants careful observation, although the revenue increase provides a mitigating factor.
📈 Company Positive News
Cipla records highest revenue of ₹28,000 crore in FY26 – scanx.trade | Cipla GST Department Inspection Concludes With No Material Impact - scanx.trade | Cipla Shares Slip Despite USFDA Nod for Generic Ventolin Inhaler; Should You Buy or Sell This Pharma Stock? - Goodreturns
🏭 Industry
The pharmaceutical sector remains relatively stable, with ongoing regulatory approvals and generic drug demand driving growth. Industry PE is currently at 34.8, suggesting moderate expectations around future earnings growth.